Bolt Biotherapeutics, Inc. (BOLT)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Collaboration revenue | 1,804 | 1,222 | 1,141 | |
| Restructuring charges | - | - | - | |
| Research and development | 7,498 | 9,512 | 13,785 | |
| General and administrative | 3,516 | 3,825 | 3,799 | |
| Total operating expense | 11,014 | 13,337 | 17,584 | |
| Loss from operations | -9,210 | -12,115 | -16,443 | |
| Other income | 50 | 22 | - | |
| Interest income, net | 599 | 1,053 | 1,267 | |
| Total other income, net | 649 | 1,075 | 1,267 | |
| Net loss | -8,561 | -11,040 | -15,176 | |
| Net unrealized loss on marketable securities | -46 | -57 | 249 | |
| Comprehensive loss | -8,607 | -11,097 | -14,927 | |
| Earnings per share, basic, total | -4.46 | -0.29 | -0.4 | |
| Earnings per share, diluted, total | -4.46 | -0.29 | -0.4 | |
| Weighted average common shares outstanding - basic | 1,917,629 | 38,339,697 | 38,250,982 | |
| Weighted average number of shares outstanding, diluted | 1,917,629 | 38,339,697 | 38,250,982 | |